Traws Pharma resubmits TXM safety data to MHRA to unlock flu challenge trial
The Phase 2a study cannot begin dosing volunteers until UK regulators clear a reworked toxicology package Traws expects to refile by the end of September.
Executive Summary
- A UK regulator's request for more preclinical safety data is now the pacing item for whether Traws Pharma's influenza challenge study opens on schedule.
- Once cleared, the study asks whether an oral antiviral already positioned for prophylaxis can prevent laboratory-confirmed infection when healthy volunteers are deliberately exposed to influenza.
- The drug sits among several oral small-molecule antivirals tested across influenza and other respiratory viral indications, but none tested in this dataset share its molecular target, leaving no direct comparator to benchmark against.
- The sponsor's broader trial history shows a completion rate built on a sizable pipeline, a base that supports confidence in operational follow-through once dosing can start.
The resubmission
Traws Pharma announced on June 22, 2026 that it is preparing a reworked toxicology data package in response to information requests from the MHRA, and expects to resubmit it during the third quarter of 2026. The company said the MHRA followed an earlier June 12 update with more detailed feedback that let Traws prepare additional preclinical safety information for the package. Chief Executive Officer Iain D. Dukes said the company believes the updated package "will support the proposed seasonal influenza Challenge study to be conducted in healthy volunteers and provide important proof of concept data for TXM's use as an oral prophylaxis medicine". Traws said it expects a formal MHRA response within 30 days of resubmission. TrawsTraws Pharma Provides Updated Guidance on Influenza Prophylaxis ProgramJun 22, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The trial this unlocks
The study is registered as NCT07503405, a Phase 2a human influenza A challenge trial testing tivoxavir marboxil against placebo in 165 healthy adults in the United Kingdom. The trial remains listed as not yet recruiting, with a start date of June 1, 2026 and a primary completion date of November 1, 2026. Its two primary endpoints are laboratory-confirmed infection and symptoms of Grade 2 or higher, measured after participants are deliberately inoculated with an influenza challenge agent. The design is a controlled human infection model in healthy volunteers, not a study in naturally infected or at-risk patients, so a positive signal establishes proof of concept for prophylactic activity rather than a treatment claim in a real-world influenza population. NCT07503405Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge ModelNCT07503405
Where TXM sits competitively
Tivoxavir marboxil is an oral small molecule, and the trial sits within a field of oral antivirals tested against influenza, COVID-19, and other respiratory viral infections, including baloxavir marboxil, suraxavir marboxil, molnupiravir, and nirmatrelvir. None of these programs share tivoxavir marboxil's molecular target in the data reviewed, so there is no direct mechanistic comparator to benchmark the challenge-study result against; the nearest context is modality precedent from other oral antivirals tested in similar human challenge or treatment designs. Chief Science Officer C. David Pauza said TXM "demonstrated broad in vitro efficacy across multiple strains of seasonal influenza and a pharmacokinetic profile consistent with its use as a chemoprophylactic agent", a claim the challenge study is designed to test in vivo. TrawsTraws Pharma Provides Updated Guidance on Influenza Prophylaxis ProgramJun 22, 2026
Sponsor execution context
Traws Pharma has run 34 trials across its pipeline, with 23 completed and three terminated, giving the company an 88% completion rate on resolved studies. That track record bears on whether the company can execute the challenge study once MHRA clears the toxicology package, though it says nothing about whether the specific resubmission will clear on the first pass. TrawsTraws Pharma Provides Updated Guidance on Influenza Prophylaxis ProgramJun 22, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.